Mereo BioPharma Group plc

Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases. Its pipeline centers on setrusumab for osteogenesis imperfecta, alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease, and a partnered early-stage bone disease program, with development funded through collaborations, licensing, and equity financing.

−7 990,0 %

−8 375,6 %

10.46

10.46

— Mereo BioPharma Group plc
%
Rare disease clinical programs0% Late-stage and early-stage drug candidates being developed for orphan and rare indications.
Setrusumab program0% Bone-disease asset for osteogenesis imperfecta with multiple regulatory designations.
Alvelestat program0% Candidate for severe alpha-1 antitrypsin deficiency-associated lung disease.
Partnered and licensed assets100% Programs monetized through collaborations, milestones, and regional rights retention.

Mereo does not sell approved commercial products; its economic counterparties are pharmaceutical partners, licensees,...

  • Pharmaceutical collaboration partnersprimary

    Companies that license assets or share development costs and pay milestones, such as ReproNovo and Ultragenyx.

  • Rare disease patients and specialist centersprimary

    Small, concentrated patient populations treated at specialized sites for OI, AATD-LD, and bone disease.

  • Clinical investigators and KOLssecondary

    Physicians and trial sites that enroll patients, generate data, and support regulatory pathways.

  • Patient advocacy groupssecondary

    Organizations that help with awareness, trial recruitment, and disease education in rare indications.

Mereo is operationally international, with development and partnering activity spanning the U.S., Europe, and the U.K...

  • •Headquartered in the United States
  • •Development and partnering activity spans the U.S. and Europe
  • •European commercial rights retained for vantictumab
  • •Setrusumab commercialization planning focuses on Europe and the U.K.
  • •Foreign currency exposure affects reported results

Mereo’s strategy is to acquire de-risked, data-rich rare-disease assets from larger pharma or biotech companies and...

01
Advance setrusumab toward approval and launch readinessshort-term

It is the most advanced rare-disease asset and a potential commercial anchor.

02
Progress alvelestat through development and regulatory stepsmedium-term

It broadens the pipeline into another orphan indication and diversifies value creation.

03
Monetize non-core assets through partnershipsshort-term

Milestones and out-licensing help fund operations without relying only on equity.

Mereo is still a development-stage biotech with no approved product sales, so its value depends on clinical success,...

high

Clinical development failure

Pipeline value depends on successful late-stage data for setrusumab and alvelestat.

Scope
Lead rare-disease programs
Materiality
high
high

Financing risk

The company expects to need additional external funding before commercialization.

Scope
Operations into 2027 and beyond
Materiality
high
medium

Foreign currency volatility

The company reported significant foreign currency transaction losses and translation gains/losses.

Scope
International operations and cash balances
Materiality
medium
medium

Partner and collaboration risk

Milestones and development progress depend on third-party partners and licensees.

Scope
ReproNovo, Ultragenyx, āshibio
Materiality
medium
Collaboration milestone revenue
The $0.5 million ReproNovo milestone drove all reported revenue in the period
Foreign currency translation and transaction effects
Foreign currency transaction losses were a major driver of period net loss
Warrant fair value accounting
Changes in fair value can materially affect reported profit or loss
R&D tax credits
Credits reduce net loss and can distort comparability across periods

GERON CORP

GERN · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

Spero Therapeutics, Inc.

SPRO · Pharmaceutical Preparations

Medivir

MVIR.ST · Health Care

: 28/04/2026